Roivant’s Lung‑Targeted Therapy Nails Phase 2 Goal, Shares Jump to Record Levels

On Tuesday the market woke up to a noticeable lift in Roivant Sciences’ (ROIV) stock price – up roughly 22% in pre‑market trades – after the company announced that its experimental lung‑disease drug Mosliciguat cleared the primary goal in a pivotal Phase 2 trial.

The study, dubbed PHocus, enrolled 135 patients with pulmonary hypertension linked to interstitial lung disease (PH‑ILD), a condition that combines scarred lung tissue with dangerously high blood‑pressure in the lungs. After 16 weeks, Mosliciguat lowered pulmonary vascular resistance (PVR) by a striking 56.3% versus placebo. In plain language, the drug made it considerably easier for the heart to push blood through the lungs.

That wasn’t the only win. Participants on Mosliciguat walked an extra 35.2 meters in a six‑minute walk test – a modest but meaningful boost for people whose daily activities are often limited by breathlessness. The trial also showed a 53.2% drop in NT‑proBNP, a blood marker that signals cardiac stress.

“PH‑ILD is as lethal as many cancers, with median survival barely two years even under the best standard of care,” said Mayukh Sukhatme, Roivant’s President and CIO. “These data put Mosliciguat in a league of its own across every efficacy read‑out we measured.”

Buoyed by the Phase 2 success, Roivant has already opened enrollment for its Phase 3 PHrontier trial, aiming to confirm the benefits in a larger, more diverse patient pool. The company estimates that up to 200,000 people across the United States and Europe could be affected by PH‑ILD.

Investors have taken note. Retail sentiment on Stocktwits flipped from bearish to bullish in the past 24 hours, and the stock, which is already up nearly 96% year‑to‑date, looks poised for its biggest single‑day rally in more than seven months if the momentum holds after the opening bell.

While many cheer the clinical milestone, some traders warn that rapid price appreciation could invite short‑selling pressure. One Stocktwits post flagged a potential short‑sell rationale, underscoring the ever‑present tug‑of‑war between optimism and caution in biotech equities.

For now, Mosliciguat’s Phase 2 data provide a glimmer of hope for a disease that has long lacked effective therapies, and they give Roivant a fresh burst of credibility in the crowded world of pulmonary‑vascular drug development.